OXFORD, Inghilterra, e CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–I pazienti con melanoma uveale metastatico (mUM) trattati con IMCgp100 continuano a presentare una risposta tumorale duratura, con un follow-up mediano di 19,1 mesi, senza tuttavia soddisfare la sopravvivenza mediana globale (OS), secondo una nuova ricerca di fase I che sarà presentata oggi al congresso annuale dell’American Society of Clinical Oncology (ASCO) a Chicago. Il testo originale del presente annuncio, redatto nella lingua di
Category: Business
New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma
OXFORD, England & CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Patients with metastatic uveal melanoma (mUM) treated with IMCgp100 continued to experience a durable tumour response with a median follow up of 19.1 months, without yet reaching median overall survival (OS), according to new Phase I research to be presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.2 IMCgp100 is the wholly-owned, lead programme from Immunocore Limited, a leading T-cell receptor (TCR
Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will pre…
Revelstoke and Cincinnati Eye Institute Form CEI Vision Partners
DENVER–(BUSINESS WIRE)–#Cincinnati–Revelstoke is pleased to announce a strategic partnership with Cincinnati Eye Institute one of the largest ophthalmology practices in the country.
Growing End-User Industries to Drive the Global Laser Materials Market | Technavio
LONDON–(BUSINESS WIRE)–#Research–Technavio’s latest market research report on the global laser materials market provides an analysis of the most important trends and drivers.
Cataract Surgery Devices – Increasing Medical Tourism for Low Cost Surgery is an Emerging Trend | Technavio
LONDON–(BUSINESS WIRE)–#CataractSurgery–Technavio’s latest market research report on the global cataract surgery devices market provides an analysis of the most important trends and drivers.
Global Ophthalmic Lasers Market 2018: Industry Analysis, Trends, Market Size and Forecasts 2016-2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lasers Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024” report has been added to ResearchAndMarkets.com’s offering. The report predicts the global ophthalmic lasers market to grow …
Wet AMD Pipeline Insight Report 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Wet AMD- Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. “Wet AMD-Pipeline Insight, 2018” report outlays comprehensive Insight of present scenario and growth prospects across Wet…
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer, AKB-4924. AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease (IBD). “Unlike other HIF stabilizers that mainly affect HIF-2 and stimulate erythropoiesi
Tear Film Innovations Completes $8.5 Million Series B Funding
SAN DIEGO–(BUSINESS WIRE)–Tear Film Innovations completes $8.5 million Series B Preferred Stock funding round led by Visionary Ventures Fund, L.P. and Bluestem Capital.
PanOptica Doses First Patient with New Formulation of PAN-90806, a Novel, Topical Anti-VEGF Eye Drop, in Phase 1/2 Clinical Trial
BERNARDSVILLE, N.J.–(BUSINESS WIRE)–PanOptica announced that it has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806
Objective Acuity Has World’s Pre-Schoolers in Its Sights
AUCKLAND, New Zealand–(BUSINESS WIRE)–Objective Acuity’s innovative vision screening test for children reduces incorrect referrals to eye specialists. Its screen test takes a few seconds.
Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients With Neovascular (wet) AMD
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–ICONIC starts second Phase 2 study
With New CEO at Helm, eyebobs Expands into Brick & Mortar Retail with Two Locations Opening Summer of 2018
MINNEAPOLIS–(BUSINESS WIRE)–eyebobs, a Minneapolis-based eyewear brand for the irreverent and slightly jaded, is proud to announce its plans to smash through the traditional eyewear retail model with the launch of two brick and mortar locations opening in the summer of 2018. The brand’s expansion is led by CEO Mike Hollenstein, who brought a wealth of previous retail experience to drive eyebobs’ 2017 launch of its prescription eyewear offerings and is now helping the brand break the mold of t
Aerpio Pharmaceuticals Announces Nomination of Industry Veteran Cheryl Cohen to Board of Directors
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced the nomination of a new director, Cheryl Cohen, to its Board of Directors. Ms. Cohen will stand for election at Aerpio’s 2018 Annual Meeting of Stockholders on June 20, 2018. If approved, Ms. Cohen will bring to Aerpio more than 25 years of experience in the biopharmaceutical industry, with a focus on strategic pr
SeniorWell Hires New Chief Technology Officer
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare company, today announced the hiring of John Clifford as Chief Technology Officer.
New Drug-eluting Contact Lens to Provide Timed Drug Delivery Directly to Eye; Improving Recovery, Reducing Cost for Millions after Eye Surgery and LASIK
MULLICA HILL, N.J.–(BUSINESS WIRE)–New Drug-eluting Contact Lens to Provide Drug Delivery Directly to Eye; Improving Recovery, Reducing Cost for Millions after Eye Surgery and LASIK
PatientPop Survey Reveals Majority of Healthcare Providers Don’t Know How to Affect Online Reputation
SANTA MONICA, Calif.–(BUSINESS WIRE)–#healthcare–PatientPop, the leader in practice growth technology, today released its 2018 Healthcare Providers Survey Report: Online Reputation Management. The nationwide survey of medical and dental professional…
Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the first quarter ended March 31, 2018. Stephen Hoffman, M.D. Ph.D., Chief Executive Officer of Aerpio, commented, “We are pleased that TIME-2b, our ongoing Phase 2b study in patients with non-proliferative diabetic retinopathy (NPDR), is fully enrolled ahead of schedule. This study will evalu